CY1124247T1 - Πρωτεϊνες συγχωνευσης υποδοχεα ενος βραχιονα τυπου ι και τυπου ii και χρηση αυτων - Google Patents
Πρωτεϊνες συγχωνευσης υποδοχεα ενος βραχιονα τυπου ι και τυπου ii και χρηση αυτωνInfo
- Publication number
- CY1124247T1 CY1124247T1 CY20211100341T CY211100341T CY1124247T1 CY 1124247 T1 CY1124247 T1 CY 1124247T1 CY 20211100341 T CY20211100341 T CY 20211100341T CY 211100341 T CY211100341 T CY 211100341T CY 1124247 T1 CY1124247 T1 CY 1124247T1
- Authority
- CY
- Cyprus
- Prior art keywords
- type
- tgf
- extracellular domain
- polypeptide complexes
- arm
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 4
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 abstract 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 abstract 2
- 102000043168 TGF-beta family Human genes 0.000 abstract 2
- 108091085018 TGF-beta family Proteins 0.000 abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
- -1 ALK5 Proteins 0.000 abstract 1
- 102100034111 Activin receptor type-1 Human genes 0.000 abstract 1
- 102100034134 Activin receptor type-1B Human genes 0.000 abstract 1
- 102100034135 Activin receptor type-1C Human genes 0.000 abstract 1
- 102100025511 Anti-Muellerian hormone type-2 receptor Human genes 0.000 abstract 1
- 101710089052 Anti-Muellerian hormone type-2 receptor Proteins 0.000 abstract 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 abstract 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 abstract 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 abstract 1
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 abstract 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 abstract 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 abstract 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000000833 heterodimer Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143579P | 2015-04-06 | 2015-04-06 | |
| US201562259422P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/026275 WO2016164501A1 (en) | 2015-04-06 | 2016-04-06 | Single-arm type i and type ii receptor fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124247T1 true CY1124247T1 (el) | 2022-07-22 |
Family
ID=57015654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100341T CY1124247T1 (el) | 2015-04-06 | 2021-04-20 | Πρωτεϊνες συγχωνευσης υποδοχεα ενος βραχιονα τυπου ι και τυπου ii και χρηση αυτων |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10358476B2 (enExample) |
| EP (2) | EP3865505A1 (enExample) |
| JP (2) | JP6810702B2 (enExample) |
| KR (1) | KR20170141215A (enExample) |
| CN (3) | CN113683708A (enExample) |
| AU (2) | AU2016246602B2 (enExample) |
| CA (1) | CA2981793A1 (enExample) |
| CY (1) | CY1124247T1 (enExample) |
| DK (1) | DK3280727T3 (enExample) |
| ES (1) | ES2864850T3 (enExample) |
| HR (1) | HRP20210411T1 (enExample) |
| HU (1) | HUE054180T2 (enExample) |
| LT (1) | LT3280727T (enExample) |
| MA (1) | MA53883A (enExample) |
| MD (1) | MD3280727T2 (enExample) |
| PL (1) | PL3280727T3 (enExample) |
| PT (1) | PT3280727T (enExample) |
| RS (1) | RS61728B1 (enExample) |
| SI (1) | SI3280727T1 (enExample) |
| SM (1) | SMT202100246T1 (enExample) |
| WO (1) | WO2016164501A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| WO2017176938A1 (en) * | 2016-04-06 | 2017-10-12 | Acceleron Pharma, Inc. | Bmprii polypeptides and uses thereof |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| EP3522912A4 (en) | 2016-10-05 | 2020-10-14 | Acceleron Pharma Inc. | HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2018144542A1 (en) * | 2017-02-01 | 2018-08-09 | Acceleron Pharma Inc. | TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
| LT3628049T (lt) * | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2019136043A1 (en) * | 2018-01-03 | 2019-07-11 | Acceleron Pharma Inc. | Single-arm co-receptor fusion proteins and uses thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| US12364736B2 (en) | 2018-02-09 | 2025-07-22 | Acceleron Pharma Inc. | Methods for treating heterotopic ossification |
| CN119431579A (zh) | 2018-03-09 | 2025-02-14 | 艾吉纳斯公司 | 抗cd73抗体及其使用方法 |
| AU2019262139A1 (en) * | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Multispecific binders of TGFβ-superfamily ligands and uses thereof |
| IL278546B2 (en) | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| KR20210063348A (ko) * | 2018-08-28 | 2021-06-01 | 이뮤노테크 바이오팜 씨오., 엘티디. | 개선된 치료용 t 세포 |
| EP3999527A4 (en) * | 2019-07-18 | 2024-04-17 | Memorial Sloan Kettering Cancer Center | METHODS AND COMPOSITIONS FOR TARGETING TGF-BETA SIGNALIZING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY |
| WO2021119136A1 (en) * | 2019-12-10 | 2021-06-17 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension |
| CN115515618A (zh) * | 2020-03-13 | 2022-12-23 | 阿塞勒隆制药公司 | 用于治疗肾脏疾病或病症的单臂ActRIIA和ActRIIB异多聚体和方法 |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| WO2021257655A1 (en) * | 2020-06-17 | 2021-12-23 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| CN112190694B (zh) * | 2020-09-17 | 2023-11-10 | 南通大学 | 细胞因子活化素c在治疗神经病理性疼痛方面的应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| WO2005028517A2 (en) * | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| AU2004274433B2 (en) | 2003-09-15 | 2010-08-12 | Research Development Foundation | Cripto antagonism of activin and TGF-beta signaling |
| BRPI0406605B8 (pt) * | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| KR20170012582A (ko) | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| TWI584815B (zh) * | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| WO2008113185A1 (en) | 2007-03-19 | 2008-09-25 | National Research Counsil Of Canada | Antagonists of ligands and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
| CN105963695A (zh) * | 2008-05-02 | 2016-09-28 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
| KR20110031951A (ko) | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| PE20150680A1 (es) * | 2008-11-26 | 2015-05-16 | Amgen Inc | Variantes de polipeptidos receptores de activina iib y aplicaciones de estos |
| CN102548617B (zh) | 2009-03-30 | 2017-11-07 | 阿塞勒隆制药公司 | Bmp‑alk3拮抗剂和促进骨生长的用途 |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| CN102712696A (zh) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| FR2951408B1 (fr) | 2009-10-15 | 2012-01-13 | Renault Sa | Cadre moteur pour moteur electrique de vehicule automobile |
| WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| EP3260130B1 (en) * | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2013149094A1 (en) | 2012-03-28 | 2013-10-03 | The Board Of Regents Of The University Of Texas System | TGFβ TYPE II-TYPE III RECEPTOR FUSIONS |
| HK1225742A1 (zh) * | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| WO2016090035A2 (en) | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| CA2980757A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| WO2016205370A1 (en) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017293778B2 (en) | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| US20180008672A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
-
2016
- 2016-04-06 CN CN202111078020.7A patent/CN113683708A/zh active Pending
- 2016-04-06 WO PCT/US2016/026275 patent/WO2016164501A1/en not_active Ceased
- 2016-04-06 KR KR1020177031992A patent/KR20170141215A/ko not_active Ceased
- 2016-04-06 HU HUE16777227A patent/HUE054180T2/hu unknown
- 2016-04-06 US US15/092,600 patent/US10358476B2/en active Active
- 2016-04-06 RS RS20210481A patent/RS61728B1/sr unknown
- 2016-04-06 LT LTEP16777227.6T patent/LT3280727T/lt unknown
- 2016-04-06 EP EP20216748.2A patent/EP3865505A1/en not_active Withdrawn
- 2016-04-06 DK DK16777227.6T patent/DK3280727T3/da active
- 2016-04-06 EP EP16777227.6A patent/EP3280727B1/en active Active
- 2016-04-06 ES ES16777227T patent/ES2864850T3/es active Active
- 2016-04-06 AU AU2016246602A patent/AU2016246602B2/en not_active Ceased
- 2016-04-06 CN CN202111078137.5A patent/CN113683709A/zh active Pending
- 2016-04-06 PL PL16777227T patent/PL3280727T3/pl unknown
- 2016-04-06 PT PT167772276T patent/PT3280727T/pt unknown
- 2016-04-06 SI SI201631118T patent/SI3280727T1/sl unknown
- 2016-04-06 MA MA053883A patent/MA53883A/fr unknown
- 2016-04-06 SM SM20210246T patent/SMT202100246T1/it unknown
- 2016-04-06 HR HRP20210411TT patent/HRP20210411T1/hr unknown
- 2016-04-06 CN CN201680033054.5A patent/CN107849114B/zh not_active Expired - Fee Related
- 2016-04-06 JP JP2017552154A patent/JP6810702B2/ja active Active
- 2016-04-06 MD MDE20180158T patent/MD3280727T2/ro unknown
- 2016-04-06 CA CA2981793A patent/CA2981793A1/en active Pending
-
2019
- 2019-05-28 US US16/423,593 patent/US11208460B2/en active Active
-
2020
- 2020-12-11 JP JP2020205943A patent/JP7203807B2/ja active Active
-
2021
- 2021-02-12 AU AU2021200906A patent/AU2021200906B2/en not_active Ceased
- 2021-04-20 CY CY20211100341T patent/CY1124247T1/el unknown
- 2021-11-10 US US17/523,226 patent/US12338273B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190016A1 (ru) | Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета | |
| CY1119172T1 (el) | ΑΝΤΙΣΩΜΑ ANTI-cMET | |
| CY1119738T1 (el) | Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων | |
| EA201591072A1 (ru) | Антитела против pdgfr-бета и их применения | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| WO2018067873A3 (en) | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof | |
| EA201790087A1 (ru) | Ковалентно связанные диатела, обладающие иммунореактивностью с pd-1 и lag-3, и способы их применения | |
| MX377844B (es) | Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso. | |
| MX388660B (es) | DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida. | |
| EA201792451A1 (ru) | Антитела к ox40 и способы их применения | |
| GEP20227419B (en) | Pd-1-binding molecules and methods of use thereof | |
| MX2016003103A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores. | |
| EA201100355A1 (ru) | Пирролопиримидины и их применение | |
| EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
| EA201800444A1 (ru) | Производные майтанзиноида, их конъюгаты и способы использования | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| EA201600190A1 (ru) | Анти-prlr антитела и их применение | |
| EA201991511A1 (ru) | Кристаллическая структура гремлин-1 и ингибирующее антитело | |
| MX390537B (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm | |
| CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| TR201809571T4 (tr) | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения |